Six months of treatment with Trikafta does not substantially alter digestive symptoms in people with cystic fibrosis (CF), new…
Articles by Marisa Wexler, MS
For children with cystic fibrosis (CF), newborn screening is associated with markedly improved real-world outcomes, including earlier…
People with cystic fibrosis (CF) who start on the triple therapy Trikafta may be at greater risk of…
Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis…
Treatment with Trikafta can help people with cystic fibrosis…
Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic…
Since the approval of Trikafta in the U.S., Nationwide Children’s Hospital in Ohio…
A platform to help people with cystic fibrosis (CF) better adhere to inhalation treatment, called the CFHealthHub, led to…
Health Canada has granted priority review to an application that seeks to expand the approval of Trikafta to cover…
Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution,…